Lysophosphatidic acid effects on atherosclerosis and thrombosis

Clinical Lipidology

Volumn 6, Issue 4, 2011, Pages 413-426

  Cui, Mei Zhen ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

atherosclerosis; lysophosphatidic acid; lysophosphatidic acid receptor; lysophospholipase D; thrombosis; vascular disease and therapeutics; vascular lesion

Indexed keywords

CHEMOKINE; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; CAUSAL ATTRIBUTION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; DENDRITIC CELL; DISEASE COURSE; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IN VIVO STUDY; LIPID DEGRADATION; LIPID OXIDATION; LIPOGENESIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 80051986975     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.38     Document Type: Review

References (168)

1. Vogt W. Pharamacologically active acidic phospholipids and glycolipids. Biochem. Pharmacol. 12, 415-420 (1963)
2. Tokumura A, Fukuzawa K, Akamatsu Y, Yamada S, Suzuki T, Tsukatani H. Identification of vasopressor phospholipid in crude soybean lecithin. Lipids 13, 468-472 (1978) (Pubitemid 8396836)
3. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am. J. Physiol. 268, H2048-H2055 (1995)
4. Schumacher KA, Classen HG, Spath M. Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb. Haemost. 42, 631-640 (1979) (Pubitemid 10229876)
5. Gerrard JM, Kindom SE, Peterson DA, Peller J, Krantz KE, White JG. Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux. Am. J. Pathol. 96, 423-438 (1979) (Pubitemid 9235956)
6. Tokumura A, Harada K, Fukuzawa K, Tsukatani H. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta 875, 31-38 (1986) (Pubitemid 16154778)
7. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59, 45-54 (1989) (Pubitemid 19248557)
8. Jalink K, van Corven EJ, Moolenaar WH. Lysophosphatidic acid, but not phosphatidic acid, is a potent Ca2+-mobilizing stimulus for fibroblasts. Evidence for an extracellular site of action. J. Biol. Chem. 265, 12232-12239 (1990)
9. Moolenaar WH. Development of our current understanding of bioactive lysophospholipids. Ann. NY Acad. Sci. 905, 1-10 (2000) (Pubitemid 30255400)
10. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135, 1071-1083 (1996) (Pubitemid 26403779)
11. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273, 7906-7910 (1998) (Pubitemid 28168837)
12. Bandoh K, Aoki J, Hosono H, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274, 27776-27785 (1999)
13. Im DS, Heise CE, Harding MA, et al. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57, 753-759 (2000) (Pubitemid 30183716)
14. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278, 25600-25606 (2003) (Pubitemid 36835313)
15. Kotarsky K, Boketoft A, Bristulf J, et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 318, 619-628 (2006) (Pubitemid 44061237)
16. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281, 23589-23597 (2006) (Pubitemid 44274133)
17. Pasternack SM, von Kugelgen I, Aboud KA, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 40, 329-334 (2008) (Pubitemid 351311768)
18. Shimomura Y, Wajid M, Ishii Y, et al. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat. Genet. 40, 335-339 (2008) (Pubitemid 351311759)
19. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl Acad. Sci. USA 97, 13384-13389 (2000)
20. Contos JJ, Ishii I, Fukushima N, et al. Characterization of LPA2 (Edg4) and LPA1/LPA2 (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22, 6921-6929 (2002)
21. Estivill-Torrus G, Llebrez-Zayas P, Matas-Rico E, et al. Absence of LPA1 signaling results in defective cortical development. Cereb. Cortex 18, 938-950 (2008) (Pubitemid 351398359)
22. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 104, 503-516 (2001)
23. Verhoye E, Langlois MR. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk? Clin. Chem. Lab. Med. 47, 128-137 (2009)
24. Ishigaki Y, Katagiri H, Gao J, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118, 75-83 (2008)
25. Libby P. Atherosclerosis: the new view. Sci. Am. 286, 46-55 (2002)
26. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924 (1989) (Pubitemid 19101597)
27. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 28, 1815-1826 (2000) (Pubitemid 30628668)
28. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227-233 (2002)
29. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436-39442 (2002) (Pubitemid 35190918)
30. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524-2529 (1992)
31. Murata J, Lee HY, Clair T, et al. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 269, 30479-30484 (1994) (Pubitemid 24376528)
32. Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92, 698-706 (2010)
33. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46, 145-160 (2007) (Pubitemid 46654231)
34. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 26, 5015-5022 (2006) (Pubitemid 43955815)
35. Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281, 25822-25830 (2006) (Pubitemid 44401970)
36. Pamuklar Z, Federico L, Lui S, et al. Autotaxin/lysophospholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J. Biol. Chem. 284, 7385-7394 (2009)
37. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 9, 415-423 (2008) (Pubitemid 351405111)
38. Pamuklar Z, Federico L, Liu S, et al. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J. Biol. Chem. 284, 7385-7394 (2009)
39. Tigyi G, Parrill AL. Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42, 498-526 (2003) (Pubitemid 37237637)
40. Brindley DN. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J. Cell. Biochem. 92, 900-912 (2004) (Pubitemid 44264240)
41. Mauco G, Chap H, Simon MF, Douste-Blazy L. Phosphatidic and lysophosphatidic acid production in phospholipase C- and thrombin-treated platelets. Possible involvement of a platelet lipase. Biochimie 60, 653-661 (1978) (Pubitemid 9018023)
42. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim. Biophys. Acta 1001, 282-285 (1989) (Pubitemid 19051284)
43. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291, 677-680 (1993) (Pubitemid 23148436)
44. Sano T, Baker D, Virag T, et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277, 21197-21206 (2002) (Pubitemid 34952255)
45. Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 96, 6931-6936 (1999) (Pubitemid 29274987)
46. Bot M, Bot I, Lopez-Vales R, et al. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. Am. J. Pathol. 176, 3073-3084 (2010)
47. Lusis AJ. Atherosclerosis. Nature 407, 233-241 (2000)
48. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005)
49. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J. Lipid Res. 50(Suppl. S), 352-357 (2009)
50. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int. J. Cardiol. 54 (Suppl. S), 21-35 (1996)
51. Sartore S, Chiavegato A, Faggin E, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. 89, 1111-1121 (2001) (Pubitemid 34627868)
52. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8, 1249-1256 (2002) (Pubitemid 35373556)
53. Rizza C, Leitinger N, Yue J, et al. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab. Invest. 79, 1227-1235 (1999) (Pubitemid 29489447)
54. Palmetshofer A, Robson SC, Nehls V. Lysophosphatidic acid activates nuclear factor kB and induces proinflammatory gene expression in endothelial cells. Thromb. Haemost. 82, 1532-1537 (1999) (Pubitemid 29527651)
55. Lee H, Lin CI, Liao JJ, et al. Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kB-dependent mechanism. Am. J. Physiol. Cell Physiol. 287, C1657-C1666 (2004) (Pubitemid 39507683)
56. Lin CI, Chen CN, Lin PW, Chang KJ, Hsieh FJ, Lee H. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem. Biophys. Res. Commun. 363, 1001-1008 (2007) (Pubitemid 47552970)
57. Shimada H, Rajagopalan LE. Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kB p65. J. Biol. Chem. 285, 12536-12542 (2010)
58. Lin CI, Chen CN, Chen JH, Lee H. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J. Cell. Biochem. 99, 1216-1232 (2006) (Pubitemid 44673976)
59. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656-660 (2003) (Pubitemid 36438080)
60. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16, 831-842 (1996) (Pubitemid 26234980)
61. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc. Med. 14, 161-165 (2004) (Pubitemid 38737336)
62. Weber KS, von Hundelshausen P, Clark- Lewis I, Weber PC, Weber C. Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur. J. Immunol. 29, 700-712 (1999) (Pubitemid 29078533)
63. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398, 718-723 (1999)
64. Gustin C, Delaive E, Dieu M, Calay D, Raes M. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler. Thromb. Vasc. Biol. 28, 491-497 (2008)
65. van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler. Thromb. Vasc. Biol. 20, E127-E133 (2000)
66. Neidlinger NA, Larkin SK, Bhagat A, Victorino GP, Kuypers FA. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J. Biol. Chem. 281, 775-781 (2006)
67. Schulze C, Smales C, Rubin LL, Staddon JM. Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J. Neurochem. 68, 991-1000 (1997) (Pubitemid 27086203)
68. Sarker MH, Hu DE, Fraser PA. Regulation of cerebromicrovascular permeability by lysophosphatidic acid. Microcirculation 17, 39-46 (2010)
69. Alexander JS, Patton WF, Christman BW, Cuiper LL, Haselton FR. Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. Am. J. Physiol. 274, H115-H122 (1998)
70. English D, Kovala AT, Welch Z, et al. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J. Hematother. Stem Cell Res. 8, 627-634 (1999) (Pubitemid 30041245)
71. Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol. Biol. Cell 9, 2639-2653 (1998) (Pubitemid 28425899)
72. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91, 3527-3561 (1998) (Pubitemid 28225719)
73. O'Brien ER, Garvin MR, Dev R, et al. Angiogenesis in human coronary atherosclerotic plaques. Am. J. Pathol. 145, 883-894 (1994) (Pubitemid 24320606)
74. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J. Pathol. 188, 189-196 (1999) (Pubitemid 29253939)
75. Di Stefano R, Felice F, Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr. Pharm. Des. 15, 1095-1106 (2009)
76. Krupinski J, Font A, Luque A, Turu M, Slevin M. Angiogenesis and inflammation in carotid atherosclerosis. Front Biosci. 13, 6472-6482 (2008)
77. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J. Pathol. 218, 7-29 (2009)
78. Kolodgie FD, Narula J, Yuan C, Burke AP, Finn AV, Virmani R. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J. Am. Coll. Cardiol. 49, 2093-2101 (2007) (Pubitemid 46771051)
79. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J. Am. Coll. Cardiol. 49, 2073-2080 (2007) (Pubitemid 46771052)
80. Lee H, Goetzl EJ, An S. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am. J. Physiol. Cell Physiol. 278, C612-C618 (2000) (Pubitemid 30154941)
81. Panetti TS, Chen H, Misenheimer TM, Getzler SB, Mosher DF. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J. Lab. Clin. Med. 129, 208-216 (1997) (Pubitemid 27134066)
82. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146, 3387-3400 (2005) (Pubitemid 41058111)
83. Langlois S, Gingras D, Beliveau R. Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103, 3020-3028 (2004) (Pubitemid 38451675)
84. Lin CI, Chen CN, Huang MT, et al. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kB activation-and EGFR transactivation-dependent mechanisms. Cell Signal. 20, 1804-1814 (2008)
85. Rivera-Lopez CM, Tucker AL, Lynch KR. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11, 301-310 (2008)
86. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75, 487-517 (1995)
87. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int. Rev. Cytol. 169, 183-265 (1996)
88. Shanahan CM, Weissberg PL. Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 18, 333-338 (1998) (Pubitemid 28125626)
89. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801 (2004) (Pubitemid 38823766)
90. Stegemann JP, Hong H, Nerem RM. Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype. J. Appl. Physiol. 98, 2321-2327 (2005) (Pubitemid 40726933)
91. Mosse PR, Campbell GR, Wang ZL, Campbell JH. Smooth muscle phenotypic expression in human carotid arteries. I. Comparison of cells from diffuse intimal thickenings adjacent to atheromatous plaques with those of the media. Lab. Invest. 53, 556-562 (1985) (Pubitemid 16204932)
92. Hayashi K, Takahashi M, Nishida W, et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 89, 251-258 (2001) (Pubitemid 34132683)
93. Guo H, Makarova N, Cheng Y, et al. The early- and late stages in phenotypic modulation of vascular smooth muscle cells: differential roles for lysophosphatidic acid. Biochim. Biophys. Acta 1781, 571-581 (2008)
94. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am. J. Pathol. 151, 697-705 (1997)
95. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108, 2070-2073 (2003) (Pubitemid 37337581)
96. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J. Cardiovasc. Pharmacol. 14(Suppl. 6), S12-S15 (1989) (Pubitemid 19267924)
97. Majesky MW, Schwartz SM. Smooth muscle diversity in arterial wound repair, Toxicol. Pathol. 18, 554-559 (1990)
98. Reidy MA. Factors controlling smooth-muscle cell proliferation. Arch. Pathol. Lab. Med. 116, 1276-1280 (1992)
99. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6, 508-519 (2006) (Pubitemid 43980523)
100. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6, 131-138 (1986) (Pubitemid 16024121)
101. Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur. Heart J. 11(Suppl. E), 3-19 (1990) (Pubitemid 20287937)
102. Ai S, Kuzuya M, Koike T, et al. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways. Atherosclerosis 155, 321-327 (2001) (Pubitemid 32209302)
103. Boguslawski G, Grogg JR, Welch Z, et al. Migration of vascular smooth muscle cells induced by sphingosine 1-phosphate and related lipids: potential role in the angiogenic response. Exp. Cell Res. 274, 264-274 (2002)
104. Damirin A, Tomura H, Komachi M, et al. Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 292, H2513-H2522 (2007) (Pubitemid 47084636)
105. Panchatcharam M, Miriyala S, Yang F, et al. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 103, 662-670 (2008)
106. Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M, Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am. J. Physiol. 267, C204-C210 (1994)
107. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl Acad. Sci. USA 85, 2805-2809 (1988)
108. Esterbauer H, Jurgens G, Quehenberger O, Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid Res. 28, 495-509 (1987) (Pubitemid 17116184)
109. Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 43, 219-225 (1992)
110. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50(Suppl.), S207-S212 (2009)
111. Leitinger N. Oxidized phospholipids as triggers of inflammation in atherosclerosis. Mol. Nutr. Food Res. 49, 1063-1071 (2005) (Pubitemid 41735566)
112. Leonarduzzi G, Chiarpotto E, Biasi F, Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol. Nutr. Food Res. 49, 1044-1049 (2005) (Pubitemid 41735564)
113. Salomon RG. Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis. Ann. NY Acad. Sci. 1043, 327-342 (2005) (Pubitemid 41123922)
114. Schmitz U, Thommes K, Beier I, Vetter H. Lysophosphatidic acid stimulates p21- activated kinase in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 291, 687-691 (2002) (Pubitemid 34687401)
115. Baldini PM, De Vito P, D'Aquilio F, et al. Role of atrial natriuretic peptide in the suppression of lysophosphatydic acid-induced rat aortic smooth muscle (RASM) cell growth. Mol. Cell Biochem. 272, 19-28 (2005) (Pubitemid 40867361)
116. Kaneyuki U, Ueda S, Yamagishi S, et al. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul. Pharmacol. 46, 286-292 (2007) (Pubitemid 46124092)
117. Hao F, Tan M, Wu DD, Xu X, Cui MZ. LPA induces IL-6 secretion from aortic smooth muscle cells via an LPA1-regulated, PKC-dependent, and p38α-mediated pathway. Am. J. Physiol. Heart Circ. Physiol. 298, H974-H983 (2010)
118. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773-778 (1999) (Pubitemid 29152622)
119. Cui MZ, Zhao G, Winokur AL. Lysophosphatidic acid induction of tissue factor expression in aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23, 224-230 (2003) (Pubitemid 36231932)
120. Edgington TS, Ruf W, Rehemtulla A, Mackman N. The molecular biology of initiation of coagulation by tissue factor. Curr. Stud. Hematol. Blood Transfus. 58, 15-21 (1991)
121. Nemerson Y. Tissue factor: then and now. Thromb. Haemost. 74, 180-184 (1995)
122. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol. Dis. 36, 104-107 (2006)
123. Taubman MB, Wang L, Miller C. The role of smooth muscle derived tissue factor in mediating thrombosis and arterial injury. Thromb. Res. 122(Suppl. 1), S78-S81 (2008)
124. Wang L, Miller C, Swarthout RF, Rao M, Mackman N, Taubman MB. Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood 113, 705-713 (2009)
125. Cui MZ, Laag E, Sun L, Tan M, Zhao G, Xu X. Lysophosphatidic acid induces early growth response gene 1 expression in vascular smooth muscle cells: CRE and SRE mediate the transcription. Arterioscler. Thromb. Vasc. Biol. 26, 1029-1035 (2006) (Pubitemid 43732108)
126. Cui MZ, Parry GC, Oeth P, et al. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J. Biol. Chem. 271, 2731-2739 (1996) (Pubitemid 26047890)
127. Cui MZ, Penn MS, Chisolm GM. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J. Biol. Chem. 274, 32795-32802 (1999) (Pubitemid 129535312)
128. Pilquil C, Dewald J, Cherney A, et al. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2- dependent phosphatidate generation. J. Biol. Chem. 281, 38418-38429 (2006) (Pubitemid 46041965)
129. Gustin C, Van Steenbrugge M, Raes M. LPA modulates monocyte migration directly and via LPA-stimulated endothelial cells. Am. J. Physiol. Cell Physiol. 295, C905-C914 (2008)
130. Zhou D, Luini W, Bernasconi S, et al. Phosphatidic acid and lysophosphatidic acid induce haptotactic migration of human monocytes. J. Biol. Chem. 270, 25549-25556 (1995)
131. Fueller M, Wang de A, Tigyi G, Siess W. Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1- phosphate. Cell Signal. 15, 367-375 (2003) (Pubitemid 36254909)
132. D'Aquilio F, Procaccini M, Izzi V, et al. Activatory properties of lysophosphatidic acid on human THP-1 cells. Inflammation 30, 167-177 (2007) (Pubitemid 47573146)
133. Lassegue B, Griendling KK. Reactive oxygen species in hypertension: an update. Am. J. Hypertens. 17, 852-860 (2004) (Pubitemid 39201104)
134. Andreadis AA, Hazen SL, Comhair SA, Erzurum SC. Oxidative and nitrosative events in asthma. Free Radic. Biol. Med. 35, 213-225 (2003) (Pubitemid 37288922)
135. Barbieri SS, Eligini S, Brambilla M, Tremoli E, Colli S. Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte to macrophage differentiation: critical role of NADPH oxidase. Cardiovasc. Res. 60, 187-197 (2003) (Pubitemid 38373491)
136. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 83, 1069-1112 (2003) (Pubitemid 37222268)
137. Beloqui O, Paramo JA, Orbe J, et al. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? Eur. Heart J. 26, 153-158 (2005) (Pubitemid 40282783)
138. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. USA 101, 11779-11784 (2004) (Pubitemid 39095371)
139. Koh JS, Lieberthal W, Heydrick S, Levine JS. Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway. J. Clin. Invest. 102, 716-727 (1998) (Pubitemid 28399604)
140. Chang C, Hsu H, Lin H, Chiang W, Lee H. Lysophosphatidic acid-induced oxidized low-density lipoprotein uptake is class A scavenger receptor-dependent in macrophages. Prostaglandins Other Lipid Mediat. 87, 20-25 (2008)
141. Kang S, Yang C, Luo R. LysoPtdOH enhances CXCL16 production stimulated by LPS from macrophages and regulates T cell migration. Lipids 43, 1075-1083 (2008)
142. Chang CL, Lin ME, Hsu HY, et al. Lysophosphatidic acid-induced interleukin-1β expression is mediated through Gi/Rho and the generation of reactive oxygen species in macrophages. J. Biomed. Sci. 15, 357-363 (2008)
143. Kimura Y, Matsushita N, Okuda H. Effects of baicalein isolated from Scutellaria baicalensis on interleukin 1β-and tumor necrosis factor-α-induced adhesion molecule expression in cultured human umbilical vein endothelial cells. J. Ethnopharmacol. 57, 63-67 (1997) (Pubitemid 27303473)
144. Bourcier T, Dockter M, Hassid A. Synergistic interaction of interleukin-1β and growth factors in primary cultures of rat aortic smooth muscle cells J. Cell Physiol. 164, 644-657 (1995)
145. Panther E, Idzko M, Corinti S, et al. The influence of lysophosphatidic acid on the functions of human dendritic cells. J. Immunol. 169, 4129-4135 (2002) (Pubitemid 35178182)
146. Oz-Arslan D, Ruscher W, Myrtek D, et al. IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids. J. Leukoc. Biol. 80, 287-297 (2006) (Pubitemid 44835502)
147. Chen R, Roman J, Guo J, et al. Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev. 15, 797-804 (2006) (Pubitemid 46147852)
148. Chan LC, Peters W, Xu Y, Chun J, Farese RV Jr, Cases S. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J. Leukoc. Biol. 82, 1193-1200 (2007) (Pubitemid 350133517)
149. Xu Y, Casey G, Mills GB. Effect of lysophospholipids on signaling in the human Jurkat T cell line. J. Cell. Physiol. 163, 441-450 (1995)
150. Zheng Y, Voice JK, Kong Y, Goetzl EJ. Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes, FASEB J. 14, 2387-2389 (2000)
151. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J. Immunol. 162, 2049-2056 (1999) (Pubitemid 29288824)
152. Zheng Y, Kong Y, Goetzl EJ. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J. Immunol. 166, 2317-2322 (2001) (Pubitemid 32173464)
153. Rubenfeld J, Guo J, Sookrung N, et al. Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L66-L74 (2006)
154. Tokumura A, Fukuzawa K, Isobe J, Tsukatani H. Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship. Biochem. Biophys. Res. Commun. 99, 391-398 (1981) (Pubitemid 12195962)
155. Haseruck N, Erl W, Pandey D, et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 103, 2585-2592 (2004) (Pubitemid 38393011)
156. Olorundare OE, Peyruchaud O, Albrecht RM, Mosher DF. Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists. Blood 98, 117-124 (2001)
157. Rother E, Brandl R, Baker DL, et al. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108, 741-747 (2003) (Pubitemid 36999261)
158. Williams JR, Khandoga AL, Goyal P, et al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J. Biol. Chem. 284, 17304-17319 (2009)
159. Tokumura A, Sinomiya J, Kishimoto S, et al. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem. J. 365, 617-628 (2002) (Pubitemid 34864443)
160. Pamuklar Z, Lee JS, Cheng HY, et al. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler. Thromb. Vasc. Biol. 28, 555-561 (2008)
161. Tokumura A, Fukuzawa K, Tsukatani H. Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids 13, 572-574 (1978) (Pubitemid 9000745)
162. Yoshida K, Nishida W, Hayashi K, et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 108, 1746-1752 (2003) (Pubitemid 37243665)
163. Zhang C, Baker DL, Yasuda S, et al. Lysophosphatidic acid induces neointima formation through PPARg activation. J. Exp. Med. 199, 763-774 (2004) (Pubitemid 38375196)
164. Cheng Y, Makarova N, Tsukahara R, et al. Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARg but not LPA1 or LPA2 GPCR. Cell Signal. 21, 1874-1884 (2009)
165. Subramanian P, Karshovska E, Reinhard P, et al. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ. Res. 107(1), 96-105 (2010)
166. Zhou Z, Subramanian P, Sevilmis G, et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 13, 592-600 (2011)
167. Hao F, Tan M, Xu X, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38a. Biochim. Biophys. Acta 1771, 883-892 (2007) (Pubitemid 46891301)
168. Chai YC, Howe PH, DiCorleto PE, Chisolm GM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J. Biol. Chem. 271, 17791-17797 (1996) (Pubitemid 26250754)